Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Sana Biotechnology
ISIN US7995661045
|WKN A2QNUE
Market cap (in EUR)
826 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 826 m |
| EPS, EUR | -0.87 |
| P/B ratio | 6.0 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | - |
| Net income, EUR | -216 m |
| Profit margin | - |
What ETF is Sana Biotechnology in?
There is 1 ETF which contains Sana Biotechnology.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.06% | Equity United States Health Care Biotech | 47 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.